Former FDA director joins ISPE
This article was originally published in Scrip
Executive Summary
The International Society for Pharmaceutical Engineering (ISPE), a not-for-profit association of 24,000 technical professionals working in the manufacturing and drug development sectors of the pharmaceutical industry, has named Anthony Celeste North America Regulatory affairs advisor. He recently retired as Kendle's senior vice-president of regulatory affairs, a position he had held since 2001. Mr Celeste also worked at the US FDA for 25 years, having last served as director of the office of regional operations, the unit responsible for managing the agency's field force of investigators, analysts, compliance officers and administrative staff.
You may also be interested in...
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.
Taro Agrees $36m Securities Settlement Over US Price-Fixing Claims
Sun’s Taro subsidiary is looking to move forward with an eight-figure settlement deal in the US, after plaintiffs including a firefighters’ pension fund accused the firm of misleading investors via its involvement in generic price fixing, leading to a fall in the price of its securities.
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.